Fish Oil Decreases C-Reactive Protein/Albumin Ratio Improving Nutritional Prognosis and Plasma Fatty Acid Profile in Colorectal Cancer Patients

Previous studies have shown that n-3 polyunsaturated fatty acids n-3 (n-3 PUFA) have several anticancer effects, especially attributed to their ability to modulate a variety of genomic and immune responses. In this context, this randomized, prospective, controlled clinical trial was conducted in ord...

Full description

Saved in:

Bibliographic Details
Published in:	Lipids Vol. 48; no. 9; pp. 879 - 888
Main Authors:	Mocellin, Michel Carlos, Pastore e Silva, Juliana de Aguiar, Camargo, Carolina de Quadros, Fabre, Maria Emília de Souza, Gevaerd, Scheila, Naliwaiko, Katya, Moreno, Yara Maria Franco, Nunes, Everson Araújo, Trindade, Erasmo Benicio Santos de Moraes
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01-09-2013 Springer Nature B.V
Subjects:	Adult Aged Animals Biomedical and Life Sciences Body Mass Index C-Reactive Protein - metabolism Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Cytokines Dietary Supplements Docosahexaenoic Acids - administration & dosage Docosahexaenoic Acids - blood Docosahexaenoic Acids - therapeutic use Drug Administration Schedule Eicosapentaenoic Acid - administration & dosage Eicosapentaenoic Acid - blood Eicosapentaenoic Acid - therapeutic use Fatty acid profile Fatty Acids - blood Female Fish oil Fish oils Fish Oils - administration & dosage Fish Oils - blood Fish Oils - therapeutic use Humans Interleukin-10 - blood Interleukin-17 - blood Interleukin-1beta - blood Life Sciences Lipidology Male Medical Biochemistry Medicinal Chemistry Microbial Genetics and Genomics Middle Aged Neurochemistry Nutrition Nutritional Status n‐3 Polyunsaturated fatty acids Original Article Polyunsaturated fatty acids Prognosis Prospective Studies Serum Albumin - metabolism Treatment Outcome Tumor Necrosis Factor-alpha - blood Chemotherapy Fatty acid profile Cytokines n-3 Polyunsaturated fatty acids Fish oil Colorectal cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Previous studies have shown that n-3 polyunsaturated fatty acids n-3 (n-3 PUFA) have several anticancer effects, especially attributed to their ability to modulate a variety of genomic and immune responses. In this context, this randomized, prospective, controlled clinical trial was conducted in order to check whether supplementation of 2 g/day of fish oil for 9 weeks alters the production of inflammatory markers, the plasma fatty acid profile and the nutritional status in patients with colorectal cancer (CRC). Eleven adults with CRC in chemotherapy were randomized into two groups: (a) supplemented (SG) daily with 2 g/day of encapsulated fish oil [providing 600 mg/day of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)] for 9 weeks ( n = 6), and (b) control (CG) ( n = 5). All outcomes were evaluated on the day before the first chemotherapy session and 9 weeks later. Plasma TNF-α, IL-1β, IL-10 and IL-17A, the pro/anti-inflammatory balance (ratio TNF-α/IL-10 and IL-1β/IL10) and serum albumin, showed no significant changes between times and study groups ( p > 0.05). C-reactive protein (CRP) and the CRP/albumin ratio showed opposite behavior in groups, significantly reducing their values in SG ( p < 0.05). Plasma proportions of EPA and DHA increased 1.8 and 1.4 times, respectively, while the ARA reduced approximately 0.6 times with the supplementation (9 weeks vs baseline, p < 0.05). Patients from SG gained 1.2 kg (median) while the CG lost −0.5 kg (median) during the 9 weeks of chemotherapy ( p = 0.72). These results demonstrate that 2 g/day of fish oil for 9 weeks of chemotherapy improves CRP values, CRP/albumin status, plasma fatty acid profile and potentially prevents weight loss during treatment.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0024-4201 1558-9307
DOI:	10.1007/s11745-013-3816-0